Download PDF
Dtsch Med Wochenschr 2007; 132(42): 2221-2224
DOI: 10.1055/s-2007-991634
Kommentar | Commentary
Prävention
© Georg Thieme Verlag KG Stuttgart · New York

Implementierung der HPV-Impfung in Deutschland

Implementation of HPV vaccination in GermanyC. Schreckenberger1 , A. M. Kaufmann1 , A. Schneider1
  • 1Klinik für Gynäkologie, Charité Universitätsmedizin Berlin
Further Information

Publication History

eingereicht: 15.5.2007

akzeptiert: 9.8.2007

Publication Date:
10 October 2007 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

HPV - Impfung - Vakzine - Zervixkarzinom - Genitalwarzen

Key words

HPV - vaccination - cervical carinoma - genital warts - screening

Literatur

  • 1 Altenhofen L. Hochrechnung zur Akzeptanz von Gesundheitsuntersuchungen und Krebsfrüherkennungsuntersuchungen bei gesetzlich Versicherten. Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland Berlin 2005
    Google Scholar
  • 2 Baseman J G, Koutsky L A. The epidemiology of human papillomavirus infections.  J Clin Virol. 2005;  32 S16-24
    Google Scholar
  • 3 Bertz J, Giersiepen K, Haberland J. et al .Krebs in Deutschland. 5. überarbeitete, aktualisierte Ausgabe. Gesellschaft der epidemiologischen Krebsregister in Deutschland e. V. und das RKI Saarbrücken 2006
    Google Scholar
  • 4 Block S L, Nolan T, Sattler C. et al . Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.  Pediatrics. 2006;  118 2135-2145
    Google Scholar
  • 5 Bryan J T, Smith J F, Ruiz W, Brownlow M K, Brown M J, Esser M T. Evaluation of antibodies induced by an HPV vaccine to cross-neutralize pseudovirions fo vaccine-related HPV types.  J Clin Oncol ASCO Annual Meeting Proceedings Part I. 2006;  24 (18S) 15008
    Google Scholar
  • 6 Carter J J, Koutsky L A, Hughes J P. et al . Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection.  J Infect Dis. 2000;  181 (6) 1911-9
    Google Scholar
  • 7 Castellsague X, Diaz M, de Sanjose S. et al . Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.  J Natl Cancer Inst. 2006;  98 303-15
    Google Scholar
  • 8 Clifford G M, Smith J S, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.  Br J Cancer. 2003;  88 (1) 63-73
    Google Scholar
  • 9 Durst M, Gissmann L, Ikenberg H, zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.  Proc Natl Acad Sci USA. 1983;  80 3812-5
    Google Scholar
  • 10 Fachinformation Gardasil. Merck C., inc., Whitehouse station, NJ 08889, U.S.A. 2006
    Google Scholar
  • 11 FUTURE II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.  N Engl J Med. 2007;  356 (19) 1915-27
    Google Scholar
  • 12 Garland S M, Hernandez-Avila M, Wheeler C M. et al, for the Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators . Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases.  N Engl J Med. 2007;  356 1928-43
    Google Scholar
  • 13 Gieseking F, Petry K U, Hillemanns P, Germé M, Littlewood K J, Bénard S, Breugelmanns J G. Incidence, prevalence and costs of treating genital warts in the pre-HPV vaccine era in Germany, 2005.  Value in Health. 2005;  8 (6) A64-65
    Google Scholar
  • 14 Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch H G, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers.  Proc Natl Acad Sci U S A. 1983;  80 (2) 560-3
    Google Scholar
  • 15 Gross G. Für das Deutsche HPV-Management-Forum Wer sollte wann, wo und wie geimpft werden?.  Dtsch Ärzteblatt. 2006;  103 (50) 3384-3388
    Google Scholar
  • 16 Harper D M, Franco E L, Wheeler C. et al . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women.  Lancet. 2004;  364 1757-65
    Google Scholar
  • 17 Harper D M, Franco E L, Wheeler C M. et al . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18.  Lancet. 2006;  367 1247-55
    Google Scholar
  • 18 Munoz N, Bosch F X, de Sanjose S. et al . Epidemiologic classification of human papillomavirus types associated with cervical cancer.  N Engl J Med. 2003;  348 518-27
    Google Scholar
  • 19 Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.  CA Cancer J Clin. 2005;  55 74-108
    Google Scholar
  • 20 Peto J, Gilham C, Fletcher O, Matthews F E. The cervical cancer epidemic that screening has prevented in the UK.  Lancet. 2004;  364 (9430) 249-56
    Google Scholar
  • 21 Petry K U, Hillemanns P, Germé M, Littlewood K J, Bérnard S, Breugelmans J G. Resource use and costs associated with the managementof PAP III, PAP IIID and PAP IV in the pre-HPV vaccine era in Germany.  Value in Health. 2005;  8 (6) A64
    Google Scholar
  • 22 Robert Koch Institut .Dachdokumentation Krebs, www.rki.de . Abfrage: 03.01.2006.
    Google Scholar
  • 23 Robert Koch Institut . Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren - Empfehlung und Begründung.  Epidemiol Bull. 2007;  12 97-103
    Google Scholar
  • 24 Smith H O, Tiffany M F, Qualls C R, Key C R. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States.  Gynecol Oncol. 2000;  78 97-105
    Google Scholar
  • 25 Statistisches Bundesamt .Krankheitskosten 2002. Statistisches Bundesamt Wiesbaden 2004
    Google Scholar
  • 26 Statistisches Bundesamt .Gesundheitsberichterstattung, Todesursachenstatistik, www.gbe-bund.de, Abfrage: 03.01.2006. 
    Google Scholar
  • 27 Taira A V, Neukermans C P, Sanders G D. Evaluating human papillomavirus vaccination programs.  Emerg Infect Dis. 2004;  10 (11) 1915-23
    Google Scholar
  • 28 Villa L L, Costa R L, Petta C A. et al . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women.  Lancet Oncol. 2005;  6 271-8
    Google Scholar
  • 29 Villa L L, Costa R L, Petta C A. et al . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up.  Br J Cancer. 2006a;  95 (11) 1459-66
    Google Scholar
  • 30 Villa L L, Ault K A, Giuliano A R. et al . Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18.  Vaccine. 2006b;  24 (27-28) 5571-83
    Google Scholar
  • 31 Viscidi R P, Schiffman M, Hildesheim A. et al . Seroreacitivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.  Cancer Epidemiol Biomarkers Prev. 2004;  13 324-327
    Google Scholar
  • 32 Walboomers J M, Jacobs M V, Manos M M. et al . Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.  J Pathol. 1999;  189 12
    Google Scholar
  • 33 zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application.  Nat Rev Cancer. 2002;  2 (5) 342-50
    Google Scholar
  • 34 Schneider A, Schwarz T F, Hammerschmidt T, Siebert U. Einfluss einer Impfung gegen humane Papillomviren auf die Inzidenz und Mortalität von Zervixkarzinom in Deutschland.  Med Klin. 2007;  102 (7) 515-523
    Google Scholar

Prof. Dr. med. Achim Schneider, M. P. H. 

Klinik für Gynäkologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin

Hindenburgdamm 30

12200 Berlin

Phone: 030/8445-2591

Fax: 030/8445-4477

Email: achim.schneider@charite.de

      >